CRISPR Therapeutics AG ($CRSP) Stock Forecast: Down 5.5% Today

What is CRISPR Therapeutics AG?

CRISPR Therapeutics AG (CRSP) is a biotech company specializing in gene editing technologies, with a focus on developing transformative therapies for genetic disorders. Today, the stock experienced a bearish movement amidst a bullish broader market.

Why is CRISPR Therapeutics AG going down?

CRSP stock is down 5.5% on Jan 30, 2026 19:35

• Maintained a buy rating on CRSP but slightly lowered its price objective, citing revised projections for Casgevy 2026. This adjustment may have contributed to some uncertainty among investors.
• The Chief Marketing Officer's significant stock purchase indicates confidence in the company's future, contrasting with the stock's decline. This move might not have been sufficient to offset broader market sentiment.
• Despite positive strategic priorities announced by CRISPR Therapeutics, the stock underperformed the market, possibly due to analysts' concerns about upcoming earnings and revenue declines.
• Investor scrutiny following the CEO's share sale and Casgevy rollout may have added to the negative sentiment, with trimmed earnings estimates and highlighted execution risks impacting the stock's performance.

CRSP Price Chart

CRSP Technical Analysis

CRSP News

BofA is Bullish on CRISPR Therapeutics AG (CRSP)

BofA maintained a buy rating on CRISPR Therapeutics AG (CRSP) despite slightly lowering its price objective from $90 to $89 due to revised Casgevy 2026 projections. The firm still anticipates consecutive improvement for Casgevy throughout 2026 and expects regulatory submissions for younger patients and advancements in other clinical programs. CRISPR Therapeutics announced strategic priorities for 2026, including Casgevy's global commercialization and clinical trial initiations for new therapies.

https://sg.finance.yahoo.com/news/bofa-bullish-crispr-therapeutics-ag-121808864.html

Top Executive Makes Bold Move With Fresh Crispr Therapeutics AG Stock Buy

The Chief Marketing Officer of Crispr Therapeutics AG, Naimish Patel, recently purchased 1,508 shares of the company's stock for $49,703, indicating confidence in the firm's future. TipRanks' AI Analyst, Spark, rates CRSP as "Neutral" due to weak financial performance despite a solid balance sheet. The stock's year-to-date performance is 4.21%, with a current market cap of $5.21 billion.

https://www.tipranks.com/news/insider-trading/top-executive-makes-bold-move-with-fresh-crispr-therapeutics-ag-stock-buy-insider-trading

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why

CRISPR Therapeutics AG (CRSP) stock dropped 1.57% while the broader market gained, closing at $54.65. Analysts anticipate a significant year-over-year decline in upcoming earnings and revenue. The stock currently holds a Zacks Rank of #3 (Hold), with the industry ranking in the top 36%.

https://www.sharewise.com/us/news_articles/CRISPR_Therapeutics_AG_CRSP_Stock_Sinks_As_Market_Gains_Heres_Why_Zacks_20260126_2350

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why

CRISPR Therapeutics AG (CRSP) stock fell by 1.57%, underperforming the broader market which saw gains in the S&P 500, Dow, and Nasdaq. Analysts anticipate a significant year-over-year decline in earnings and revenue for CRSP's upcoming financial report. The company currently holds a Zacks Rank of #3 (Hold), with its industry ranked in the top 36%.

https://au.finance.yahoo.com/news/crispr-therapeutics-ag-crsp-stock-225003780.html

Did CEO Share Sale and Casgevy Rollout Just Shift CRISPR Therapeutics' (CRSP) Investment Narrative?

CRISPR Therapeutics is under investor scrutiny due to a pre-arranged share sale by CEO Samarth Kulkarni and the early commercial rollout of its gene-edited therapy, Casgevy. While analysts maintain constructive views, near-term earnings estimates have been trimmed, highlighting execution risks and potential dilution. The company's future hinges on Casgevy's commercial uptake and progress in other pipeline programs.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/did-ceo-share-sale-and-casgevy-rollout-just-shift-crispr-the

Trending Today

Lemonda Inc. ($LMND) Stock Forecast: Down 7.0% Today

GlobalFoundries Inc. ($GFS) Stock Forecast: Down 5.2% Today

Astera Labs Inc ($ALAB) Stock Forecast: Down 5.5% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Down 5.0% Today

Take-Two Interactive Software Inc. ($TTWO) Stock Forecast: Down 9.1% Today

Freeport-McMoRan Inc. ($FCX) Stock Forecast: Down 6.6% Today

Newmont Mining Corporation ($NEM) Stock Forecast: Down 10.7% Today

KLA-Tencor Corporation ($KLAC) Stock Forecast: Down 15.5% Today

Lam Research Corporation ($LRCX) Stock Forecast: Down 5.8% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Down 5.2% Today

CRISPR Therapeutics AG Price History

10.09.2025 - CRSP Stock was down 5.1%

• CRSP stock saw a significant bearish movement, dropping by 6.98% to close at $67.74.
• The stock's decline was more pronounced than the broader market trend, indicating specific factors impacting CRISPR Therapeutics AG.
• The dip in CRSP stock could be attributed to potential concerns over the company's research and development pipeline or general market volatility affecting biotech stocks.
• Investors may be closely monitoring any updates on CRISPR Therapeutics' clinical trials, regulatory approvals, or competitive landscape to gauge the stock's future performance.

31.09.2025 - CRSP Stock was up 5.8%

• Despite a -2.51% change from the previous close, the market movement for CRSP today was bullish.
• The slight decrease in stock price may be due to profit-taking by some investors following a recent uptrend.
• Positive sentiment towards the company's gene-editing technology and future growth prospects likely fueled the bullish movement.
• Investors' optimism about CRSP's pipeline of gene therapies and their potential to address unmet medical needs could be boosting the stock price.

22.11.2025 - CRSP Stock was up 5.2%

• The recent rise in CRSP stock value may be linked to a reevaluation of the company's worth following a recent decline, highlighting its strong performance so far this year and potential undervaluation based on a Discounted Cash Flow model.
• Despite concerns about the slow adoption of its gene-editing therapy Casgevy, there appears to be a positive outlook on CRISPR Therapeutics' future prospects, particularly given the stock's strong performance compared to its sector and the broader market in the past month.
• Anticipated lower earnings and revenue in the upcoming financial report may have already been considered in the stock price, leading to increased optimism among investors who are focusing on the long-term potential of CRISPR Therapeutics' project portfolio rather than short-term obstacles.

22.09.2025 - CRSP Stock was down 6.3%

• Today's downward trend in CRSP stock could be linked to profit-taking by investors following a recent uptick in its price.
• The -2.24% drop might also be influenced by broader market sentiments or shifts within the biotech sector.
• Investor reactions may be tied to potential negative updates or uncertainties surrounding the company's clinical trials, regulatory challenges, or competitive landscape in gene editing.
• It is crucial for investors to stay informed about the company's pipeline progress and regulatory changes to evaluate the future trajectory of CRSP stock.

06.00.2026 - CRSP Stock was up 5.5%

• Today's upward movement in CRSP stock is linked to the increased investor interest post its participation in the J.P. Morgan Healthcare Conference, highlighting groundbreaking medicines like CASGEVY®.
• The company's perceived undervaluation, evident in its price-to-book ratio and discounted cash flow model in comparison to competitors, has likely attracted investors seeking potential growth opportunities.
• Although the stock recently experienced a decline relative to the broader market, the upcoming earnings report, forecasting an EPS of -$1.16 and revenue of $4 million, holds promise for a potential turnaround in the stock's performance.
• The endorsement from Chardan to buy shares further contributes to the positive outlook on CRSP, signifying faith in the company's future trajectory and growth possibilities.

06.00.2026 - CRSP Stock was up 10.9%

• Investor interest in CRISPR Therapeutics is growing due to its undervalued position in comparison to peers and its intrinsic value, despite sustained losses.
• Although there was a recent decline in the stock price, upcoming earnings are expected to be slightly negative according to analysts, prompting investors to closely monitor future performance.
• Key factors for potential stock movements include the company's collaboration with Vertex Pharmaceuticals and the introduction of its gene-editing therapy, Casgevy.
• Chardan's reiterated "buy" recommendation and positive clinical updates on Zugo-cel are bolstering the bullish momentum in CRSP stock.

10.10.2025 - CRSP Stock was down 5.0%

• CRSP stock dropped by -2.56% despite overall market gains.
• The bearish movement may be due to profit-taking by investors after a growth period.
• Concerns about the company's future earnings potential or regulatory challenges could be influencing investors.
• Monitoring upcoming developments in the biotech sector that could affect CRSP's stock performance is important.

23.00.2026 - CRSP Stock was up 6.3%

• An insider's sale of shares worth $5.2 million initially raised some concerns among investors, causing a slight dip in the stock price during premarket trading.
• Despite the selling activity, the positive announcement of Casgevy therapy exceeding $100 million in revenue by 2025 and the expected regulatory submissions for younger patients with specific ailments bolstered investor confidence, leading to a significant increase in the stock price.
• Varying analyst opinions and valuation methods indicate short-term fluctuations due to insider transactions, but the long-term growth potential and advancements in gene editing technology position CRISPR Therapeutics for sustained success in the gene therapy sector.
• Taken together, the CEO's share sale, favorable revenue updates, progress in clinical trials, and expert analyses likely drove the upward momentum in CRSP stock today.

22.00.2026 - CRSP Stock was up 6.2%

• CRISPR Therapeutics (CRSP) saw a significant uptrend in its stock performance today, potentially influenced by the following key factors:
• Recent advancements in gene editing have instilled optimism among investors, leading to a notable undervaluation of the company based on a Discounted Cash Flow analysis.
• Various analyst ratings, including a Buy recommendation from Bank of America Securities with a target price of $90.00, have also positively impacted market sentiment towards CRSP.
• A substantial 455.7% increase in stake by Nwam LLC during Q3 could be interpreted as a vote of confidence in the company's long-term outlook, despite falling short of revenue expectations in the same period.
• The unveiling of CRISPR Therapeutics' 2026 strategic roadmap, emphasizing global commercialization efforts and regulatory submissions, has offered investors a peek into potential future growth prospects, helping to counter recent declines in the stock price.

30.00.2026 - CRSP Stock was down 5.5%

• Maintained a buy rating on CRSP but slightly lowered its price objective, citing revised projections for Casgevy 2026. This adjustment may have contributed to some uncertainty among investors.
• The Chief Marketing Officer's significant stock purchase indicates confidence in the company's future, contrasting with the stock's decline. This move might not have been sufficient to offset broader market sentiment.
• Despite positive strategic priorities announced by CRISPR Therapeutics, the stock underperformed the market, possibly due to analysts' concerns about upcoming earnings and revenue declines.
• Investor scrutiny following the CEO's share sale and Casgevy rollout may have added to the negative sentiment, with trimmed earnings estimates and highlighted execution risks impacting the stock's performance.

14.09.2025 - CRSP Stock was down 10.4%

• CRSP stock saw a more significant decline compared to the broader market, ending at $68.29, reflecting a -6.54% change from the previous day, indicating a bearish trend.
• The stock's notable drop could be linked to profit-taking activities by investors following a recent price surge or concerns regarding the company's pipeline or financial results.
• Despite the market's positive performance, specific internal factors within CRSP such as regulatory challenges, clinical trial outcomes, or alterations in analyst outlooks might have influenced its stock decline.
• Investors are likely keeping a close watch on developments in the biotech industry and updates on CRISPR technology that could impact CRSP's stock movement in the near future.

08.00.2026 - CRSP Stock was down 5.3%

• The bearish movement in CRISPR Therapeutics AG (CRSP) today could be due to:
• Despite positive sentiment from institutional investors and analyst recommendations, the stock may have experienced profit-taking after a significant gain in market cap last week.
• The varying assessments of the stock's valuation, with a DCF analysis pointing towards undervaluation and the P/B ratio indicating fair pricing, might have resulted in investor uncertainty.
• Investor interest and attention refocusing on CRSP could have led to increased volatility as market participants reassess the company's potential growth opportunities and risks linked to its pipeline programs.
• The anticipation surrounding the upcoming presentation at the J.P. Morgan Healthcare Conference may have heightened expectations, prompting a sell-off as investors await further details or guidance from the management team.